Home » GENAISSANCE ENTERS INTO HAP(TM) TECHNOLOGY LICENSE AGREEMENT WITH SANKYO
GENAISSANCE ENTERS INTO HAP(TM) TECHNOLOGY LICENSE AGREEMENT WITH SANKYO
Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) today announced that it has entered into an agreement with Sankyo, Co., Ltd. (TSE: 4501), under which the companies will apply Genaissance's HAP(TM) Technology in conjunction with the focused therapeutic areas of Sankyo. The goal of the collaboration is to discover genetic markers related to drug response and then validate these genetic markers and create a companion diagnostic test that will guide therapy.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-03-2005/0004157726&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May